Compare FRMI & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRMI | IMVT |
|---|---|---|
| Founded | 2025 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.3B |
| IPO Year | 2025 | N/A |
| Metric | FRMI | IMVT |
|---|---|---|
| Price | $7.61 | $26.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $30.86 | $27.75 |
| AVG Volume (30 Days) | ★ 8.2M | 1.9M |
| Earning Date | 01-28-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.52 | $12.72 |
| 52 Week High | $36.99 | $27.69 |
| Indicator | FRMI | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 58.44 |
| Support Level | N/A | $26.35 |
| Resistance Level | N/A | $27.64 |
| Average True Range (ATR) | 0.00 | 1.39 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 0.00 | 71.64 |
Fermi Inc is an energy and hyperscaler development company purpose-built for the AI era. Its Project Matador, a multi-gigawatt energy and data center development campus designed to support the accelerating needs of to-be-built AI infrastructure. Through its REIT structure, Fermi offers investors exposure to AI infrastructure growth and long-term, large-scale and reliable energy development in a tax-efficient public vehicle.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.